Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2097 entries
Sorted by: Best Match Show Resources per page
Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.

Journal of the advanced practitioner in oncology

Silva NN, Eng C.
PMID: 25031942
J Adv Pract Oncol. 2012 May;3(3):161-9. doi: 10.6004/jadpro.2012.3.3.4.

Case Study Ms. S.G., a 56-year-old woman with a poorly differentiated squamous cell carcinoma of the anal canal, American Joint Committee on Cancer stage III (T2, N1, M0), was initially diagnosed in December, 2007 at an outside institution after...

Cite
Silva NN, Eng C. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. J Adv Pract Oncol. 2012;3(3):161-9doi: 10.6004/jadpro.2012.3.3.4.
Silva, N. N., & Eng, C. (2012). Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. Journal of the advanced practitioner in oncology, 3(3), 161-9. https://doi.org/10.6004/jadpro.2012.3.3.4
Silva, Ninoska N, and Eng, Cathy. "Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy." Journal of the advanced practitioner in oncology vol. 3,3 (2012): 161-9. doi: https://doi.org/10.6004/jadpro.2012.3.3.4
Silva NN, Eng C. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. J Adv Pract Oncol. 2012 May;3(3):161-9. doi: 10.6004/jadpro.2012.3.3.4. PMID: 25031942; PMCID: PMC4093318.
Copy Download .nbib Format: NLM
Brentuximab Vedotin Infusion Reaction Management: A Case Study.

Journal of the advanced practitioner in oncology

Comer H, Cardwell K.
PMID: 30310723
J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 01.

We report a case of a grade 3 (Common Terminology Criteria for Adverse Events [CTCAE]) infusion reaction to brentuximab vedotin (Adcetris), in a patient with refractory Hodgkin lymphoma, at a large National Cancer Institute-designated cancer center in the Midwest...

Cite
Comer H, Cardwell K. Brentuximab Vedotin Infusion Reaction Management: A Case Study. J Adv Pract Oncol. 2017;8(6):626-629
Comer, H., & Cardwell, K. (2017). Brentuximab Vedotin Infusion Reaction Management: A Case Study. Journal of the advanced practitioner in oncology, 8(6), 626-629.
Comer, Holly, and Cardwell, Kimbra. "Brentuximab Vedotin Infusion Reaction Management: A Case Study." Journal of the advanced practitioner in oncology vol. 8,6 (2017): 626-629.
Comer H, Cardwell K. Brentuximab Vedotin Infusion Reaction Management: A Case Study. J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 01. PMID: 30310723; PMCID: PMC6167082.
Copy Download .nbib Format: NLM
The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).

International journal of oncology

Chaney S.
PMID: 21556672
Int J Oncol. 1995 Jun;6(6):1291-305. doi: 10.3892/ijo.6.6.1291.

Dach-Pt compounds have been intensively studied because of their potential. efficacy against cisplatin-resistant tumors and their reduced nephrotoxicity and myelotoxicity compared to cisplatin and carboplatin. Because the dach carrier ligand can be H-3-labeled, the biotransformations of dach-Pt compounds have...

Cite
Chaney S. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). Int J Oncol. 1995;6(6):1291-305doi: 10.3892/ijo.6.6.1291.
Chaney, S. (1995). The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). International journal of oncology, 6(6), 1291-305. https://doi.org/10.3892/ijo.6.6.1291
Chaney, S. "The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review)." International journal of oncology vol. 6,6 (1995): 1291-305. doi: https://doi.org/10.3892/ijo.6.6.1291
Chaney S. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). Int J Oncol. 1995 Jun;6(6):1291-305. doi: 10.3892/ijo.6.6.1291. PMID: 21556672.
Copy Download .nbib Format: NLM
Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC.

Case reports in oncology

Cheng Y, Li N, Eapen A, Parajuli R, Mehta R.
PMID: 31320873
Case Rep Oncol. 2019 Jun 26;12(2):494-499. doi: 10.1159/000501304. eCollection 2019.

Accessory male breast cancer (BC) is a rare entity and is associated with poor outcome. We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation....

Cite
Cheng Y, Li N, Eapen A, et al. Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. Case Rep Oncol. 2019;12(2):494-499doi: 10.1159/000501304.
Cheng, Y., Li, N., Eapen, A., Parajuli, R., & Mehta, R. (2019). Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. Case reports in oncology, 12(2), 494-499. https://doi.org/10.1159/000501304
Cheng, Yu, et al. "Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC." Case reports in oncology vol. 12,2 (2019): 494-499. doi: https://doi.org/10.1159/000501304
Cheng Y, Li N, Eapen A, Parajuli R, Mehta R. Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. Case Rep Oncol. 2019 Jun 26;12(2):494-499. doi: 10.1159/000501304. eCollection 2019. PMID: 31320873; PMCID: PMC6616081.
Copy Download .nbib Format: NLM
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.

The Lancet. Oncology

Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J.
PMID: 35038432
Lancet Oncol. 2022 Jan 14; doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14.

BACKGROUND: PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there was no robust evidence showing a PD-L1 inhibitor combined with chemotherapy benefited patients with squamous...

Cite
Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022;doi: 10.1016/S1470-2045(21)00650-1.
Zhou, C., Wang, Z., Sun, Y., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Chang, J., Chen, J., Zhuang, W., Cui, J., Chen, X., Lu, Y., Shen, H., Wang, J., Li, P., Qin, M., Lu, D., & Yang, J. (2022). Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. The Lancet. Oncology, . https://doi.org/10.1016/S1470-2045(21)00650-1
Zhou, Caicun, et al. "Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial." The Lancet. Oncology vol. (2022). doi: https://doi.org/10.1016/S1470-2045(21)00650-1
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022 Jan 14; doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. PMID: 35038432.
Copy Download .nbib Format: NLM
Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225].

European journal of cancer (Oxford, England : 1990)

Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio Perilongo, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL.
PMID: 29248309
Eur J Cancer. 2018 Feb;90:156-157. doi: 10.1016/j.ejca.2017.11.017. Epub 2017 Dec 14.

No abstract available.

Cite
Gnekow AK, Walker DA, Kandels D, et al. Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225]. Eur J Cancer. 2017;90:156-157doi: 10.1016/j.ejca.2017.11.017.
Gnekow, A. K., Walker, D. A., Kandels, D., Picton, S., Giorgio Perilongo, Grill, J., Stokland, T., Sandstrom, P. E., Warmuth-Metz, M., Pietsch, T., Giangaspero, F., Schmidt, R., Faldum, A., Kilmartin, D., De Paoli, A., De Salvo, G. L. (2018). Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225]. European journal of cancer (Oxford, England : 1990), 90156-157. https://doi.org/10.1016/j.ejca.2017.11.017
Gnekow, Astrid K, et al. "Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225]." European journal of cancer (Oxford, England : 1990) vol. 90 (2018): 156-157. doi: https://doi.org/10.1016/j.ejca.2017.11.017
Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio Perilongo, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL. Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225]. Eur J Cancer. 2018 Feb;90:156-157. doi: 10.1016/j.ejca.2017.11.017. Epub 2017 Dec 14. PMID: 29248309; PMCID: PMC6854447.
Copy Download .nbib Format: NLM
Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.

JAMA network open

Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D.
PMID: 34019086
JAMA Netw Open. 2021 May 03;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113.

IMPORTANCE: Immunotherapy is now a cornerstone of treatment for advanced non-small cell lung cancer (NSCLC), but its uptake and effectiveness among older patients outside clinical trials remain poorly understood.OBJECTIVE: To understand treatment patterns and evaluate the overall survival associated...

Cite
Kehl KL, Greenwald S, Chamoun NG, et al. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2021;4(5):e2111113doi: 10.1001/jamanetworkopen.2021.11113.
Kehl, K. L., Greenwald, S., Chamoun, N. G., Manberg, P. J., & Schrag, D. (2021). Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA network open, 4(5), e2111113. https://doi.org/10.1001/jamanetworkopen.2021.11113
Kehl, Kenneth L, et al. "Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer." JAMA network open vol. 4,5 (2021): e2111113. doi: https://doi.org/10.1001/jamanetworkopen.2021.11113
Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2021 May 03;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113. PMID: 34019086; PMCID: PMC8140374.
Copy Download .nbib Format: NLM
Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.

JAMA network open

Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D.
PMID: 34019086
JAMA Netw Open. 2021 May 03;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113.

IMPORTANCE: Immunotherapy is now a cornerstone of treatment for advanced non-small cell lung cancer (NSCLC), but its uptake and effectiveness among older patients outside clinical trials remain poorly understood.OBJECTIVE: To understand treatment patterns and evaluate the overall survival associated...

Cite
Kehl KL, Greenwald S, Chamoun NG, et al. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2021;4(5):e2111113doi: 10.1001/jamanetworkopen.2021.11113.
Kehl, K. L., Greenwald, S., Chamoun, N. G., Manberg, P. J., & Schrag, D. (2021). Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA network open, 4(5), e2111113. https://doi.org/10.1001/jamanetworkopen.2021.11113
Kehl, Kenneth L, et al. "Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer." JAMA network open vol. 4,5 (2021): e2111113. doi: https://doi.org/10.1001/jamanetworkopen.2021.11113
Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2021 May 03;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113. PMID: 34019086; PMCID: PMC8140374.
Copy Download .nbib Format: NLM
DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.

Journal of cancer stem cell research

Kakar SS, Worth CA, Wang Z, Carter K, Ratajczak M, Gunjal P.
PMID: 27668267
J Cancer Stem Cell Res. 2016;4. doi: 10.14343/JCSCR.2016.4e1002. Epub 2016 Apr 19.

Ovarian cancer is a highly aggressive and deadly disease. Currently, the treatment for ovarian cancer entails cytoreductive surgery followed by chemotherapy, mainly cisplatin or carboplatin combined with paclitaxel. Although this regimen is initially effective in a high percentage of...

Cite
Kakar SS, Worth CA, Wang Z, et al. DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J Cancer Stem Cell Res. 2016;4doi: 10.14343/JCSCR.2016.4e1002.
Kakar, S. S., Worth, C. A., Wang, Z., Carter, K., Ratajczak, M., & Gunjal, P. (2016). DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. Journal of cancer stem cell research, 4. https://doi.org/10.14343/JCSCR.2016.4e1002
Kakar, Sham S, et al. "DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer." Journal of cancer stem cell research vol. 4 (2016). doi: https://doi.org/10.14343/JCSCR.2016.4e1002
Kakar SS, Worth CA, Wang Z, Carter K, Ratajczak M, Gunjal P. DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J Cancer Stem Cell Res. 2016;4. doi: 10.14343/JCSCR.2016.4e1002. Epub 2016 Apr 19. PMID: 27668267; PMCID: PMC5033248.
Copy Download .nbib Format: NLM
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.

European urology oncology

Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.
PMID: 33423945
Eur Urol Oncol. 2021 Jun;4(3):464-472. doi: 10.1016/j.euo.2020.12.006. Epub 2021 Jan 07.

BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers...

Cite
Khaki AR, Li A, Diamantopoulos LN, et al. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021;4(3):464-472doi: 10.1016/j.euo.2020.12.006.
Khaki, A. R., Li, A., Diamantopoulos, L. N., Miller, N. J., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Koshkin, V., Park, J., Alva, A., Bilen, M. A., Stewart, T., Santos, V., Agarwal, N., Jain, J., Zakharia, Y., Morales-Barrera, R., Devitt, M., Nelson, A., Hoimes, C. J., Shreck, E., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Kumar, V., Lythgoe, M. P., Pinato, D. J., Murgic, J., Fröbe, A., Joshi, M., Isaacsson Velho, P., Hahn, N., Alonso Buznego, L., Duran, I., Moses, M., Barata, P., Galsky, M. D., Sonpavde, G., Yu, E. Y., Shankaran, V., Lyman, G. H., & Grivas, P. (2021). A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European urology oncology, 4(3), 464-472. https://doi.org/10.1016/j.euo.2020.12.006
Khaki, Ali Raza, et al. "A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors." European urology oncology vol. 4,3 (2021): 464-472. doi: https://doi.org/10.1016/j.euo.2020.12.006
Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 Jun;4(3):464-472. doi: 10.1016/j.euo.2020.12.006. Epub 2021 Jan 07. PMID: 33423945; PMCID: PMC8169524.
Copy Download .nbib Format: NLM
Vaginal mucositis related to immunotherapy in endometrial cancer.

Gynecologic oncology reports

Patel JM, Enich M, Stephenson R, Groinsberg R, Girda E.
PMID: 33948476
Gynecol Oncol Rep. 2021 Mar 31;36:100742. doi: 10.1016/j.gore.2021.100742. eCollection 2021 May.

Immunotherapy, specifically immune checkpoint inhibitors (ICPi), has revolutionized our approach to treating all solid tumors, including gynecologic malignancies. Compared to standard chemotherapy, the adverse events associated with immunotherapies, are often mild and localized, although more severe systemic responses can...

Cite
Patel JM, Enich M, Stephenson R, et al. Vaginal mucositis related to immunotherapy in endometrial cancer. Gynecol Oncol Rep. 2021;36:100742doi: 10.1016/j.gore.2021.100742.
Patel, J. M., Enich, M., Stephenson, R., Groinsberg, R., & Girda, E. (2021). Vaginal mucositis related to immunotherapy in endometrial cancer. Gynecologic oncology reports, 36100742. https://doi.org/10.1016/j.gore.2021.100742
Patel, Jharna M, et al. "Vaginal mucositis related to immunotherapy in endometrial cancer." Gynecologic oncology reports vol. 36 (2021): 100742. doi: https://doi.org/10.1016/j.gore.2021.100742
Patel JM, Enich M, Stephenson R, Groinsberg R, Girda E. Vaginal mucositis related to immunotherapy in endometrial cancer. Gynecol Oncol Rep. 2021 Mar 31;36:100742. doi: 10.1016/j.gore.2021.100742. eCollection 2021 May. PMID: 33948476; PMCID: PMC8080023.
Copy Download .nbib Format: NLM
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.

The Lancet. Oncology

Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, Hong TS, Leichman LP, Rajdev L, Resnick M, Kachnic LA, Seaward S, Mamon H, Diaz Pardo DA, Anderson CM, Shen X, Sharma AK, Katz AW, Salo J, Leonard KL, Moughan J, Crane CH.
PMID: 35038433
Lancet Oncol. 2022 Jan 14; doi: 10.1016/S1470-2045(21)00718-X. Epub 2022 Jan 14.

BACKGROUND: Trastuzumab is a monoclonal antibody against HER2 (also known as ERBB2). The primary objective of the NRG Oncology/RTOG-1010 trial was to establish whether trastuzumab improves disease-free survival when combined with trimodality treatment (paclitaxel plus carboplatin and radiotherapy, followed...

Cite
Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022;doi: 10.1016/S1470-2045(21)00718-X.
Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., Kachnic, L. A., Seaward, S., Mamon, H., Diaz Pardo, D. A., Anderson, C. M., Shen, X., Sharma, A. K., Katz, A. W., Salo, J., Leonard, K. L., Moughan, J., & Crane, C. H. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet. Oncology, . https://doi.org/10.1016/S1470-2045(21)00718-X
Safran, Howard P, et al. "Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial." The Lancet. Oncology vol. (2022). doi: https://doi.org/10.1016/S1470-2045(21)00718-X
Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, Hong TS, Leichman LP, Rajdev L, Resnick M, Kachnic LA, Seaward S, Mamon H, Diaz Pardo DA, Anderson CM, Shen X, Sharma AK, Katz AW, Salo J, Leonard KL, Moughan J, Crane CH. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022 Jan 14; doi: 10.1016/S1470-2045(21)00718-X. Epub 2022 Jan 14. PMID: 35038433.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2097 entries